Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Abstract Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with gre...

Full description

Bibliographic Details
Main Authors: Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García‐Campelo, William Edenfield, Trevor M. Feinstein, Jennifer M. Johnson, Sujith Kalmadi, Philip E. Lammers, Alfredo Sanchez‐Hernandez, Yili Pritchett, Shannon R. Morris, Rajesh K. Malik, Tibor Csőszi
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Cancer Medicine
Subjects:
anemia
erythropoiesis‐stimulating agent
granulocyte colony‐stimulating factor
neutropenia
red blood cell transfusion
trilaciclib
Online Access:https://doi.org/10.1002/cam4.4089

Internet

https://doi.org/10.1002/cam4.4089

Similar Items